WFRF:(Hjalmarson Åke 1937)
Search: WFRF:(Hjalmarson Åke 1937) > (2010-2014) > An economic evaluat...
- 3 of 4
- Previous record
- Next record
- To hitlist
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial.
- Lorgelly, Paula K (author)
- Briggs, Andrew H (author)
- Wedel, Hans (author)
- show more...
- Dunselman, Peter (author)
- Kjekshus, John (author)
- Jánosi, András (author)
- van Veldhuisen, Dirk J (author)
- Barrios, Vivencio (author)
- Fonseca, Cândida (author)
- McMurray, John J V (author)
- show less...
- (creator_code:org_t)
- 2009-12-18
- 2010
- English.
- In: European journal of heart failure. - : Wiley. - 1879-0844 .- 1388-9842. ; 12:1, s. 66-74
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- AIMS: To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial. METHODS AND RESULTS: This within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95% CI: 0.075-0.254, P < 0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin ( pound1531 vs. pound1769; difference pound238; 95% CI: pound73-403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group ( pound1769 vs. pound2072; difference pound303; 95% CI: pound138-468, P < 0.001). Overall, rosuvastatin was found to cost pound1840 (95% CI: pound562-6028) per major CV event avoided. CONCLUSION: This economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure.
Keyword
- Cost-effectiveness
- Heart failure
- Statins
- Multinational trial
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- European journal of heart failure (Search for host publication in LIBRIS)
To the university's database
- 3 of 4
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Lorgelly, Paula ...
- Briggs, Andrew H
- Wedel, Hans
- Dunselman, Peter
- Hjalmarson, Åke, ...
- Kjekshus, John
- show more...
- Waagstein, Finn, ...
- Wikstrand, John, ...
- Jánosi, András
- van Veldhuisen, ...
- Barrios, Vivenci ...
- Fonseca, Cândida
- McMurray, John J ...
- show less...
- Articles in the publication
- European journal ...
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
